华润医药(03320.HK) 宣布,集团旗下双鹤润创于10月11日获得国家药监局受理通知书,并于近日收到DC10190胶囊《药物临床试验批准通知书》,同意DC10190胶囊在晚期或转移性实体瘤患者中开展临床试验。
DC10190胶囊拟用于治疗晚期或转移性实体瘤患者,为境内外均未上市的1类新药。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-27 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.